# Intratumoral Injection of Autologous CD1c (BDCA-1)+ Myeloid Dendritic Cells Plus Talimogene Laherparepvec (T-VEC)

> **NCT03747744** · PHASE1 · UNKNOWN · sponsor: **Universitair Ziekenhuis Brussel** · enrollment: 18 (estimated)

## Conditions studied

- Melanoma

## Interventions

- **OTHER:** CD1c (BDCA-1)+ myDC

## Key facts

- **NCT ID:** NCT03747744
- **Lead sponsor:** Universitair Ziekenhuis Brussel
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-09-28
- **Primary completion:** 2023-10-01
- **Final completion:** 2023-10-01
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2020-12-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03747744

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03747744, "Intratumoral Injection of Autologous CD1c (BDCA-1)+ Myeloid Dendritic Cells Plus Talimogene Laherparepvec (T-VEC)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03747744. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*